A Phase 1 interventional study of GB-0895 (SC) and GB-0895 (SC) in Asthma and COPD (Chronic Obstructive Pulmonary Disease), sponsored by Generate Biomedicines. Active, not recruiting at 13 sites in 3 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-11-05.
Sponsored by Generate Biomedicines · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,695 studies in Asthma with a site in United States — 135 open to participants now, 188 under way, 19 of them phase 3. Asthma · United States.
Among the 1,695 studies in Asthma with a site in United States, this one is the 566th largest by planned enrollment of the 1,353 interventional ones that give a count, is one of 55 that started in 2023, is one of 128 in phase 1, reaches primary completion later than 84 of the 183 other live ones, and was the 1,632nd registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →135 of the 1,695 studies in Asthma with a site in United States are open now. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States, Argentina, China and 2 more countries
Ages 18–85
Pfizer · Sites in United States, Puerto Rico
Ages 12–80
GlaxoSmithKline · Sites in United States, Argentina, Canada and 1 more country
Ages 18+
Spiro Medical, Inc. · Sites in United States
Ages 18–75
GlaxoSmithKline · Sites in United States
Ages 12–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,695 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 151 · Phase 2 337 · Phase 3 276 · Phase 4 158
First in 1990; this study’s year is marked. 55 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 156 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 100 across the 1,353 interventional studies, 112 across the 330 observational. Of the 1,402 that completed or were terminated, 626 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
642 of 1,695 have an industry lead sponsor. The 10 most frequent:
Generate Biomedicines is the lead sponsor of 6 studies on the registry; 3 are open to participants now.
Generate Biomedicines has 3 studies filed under Asthma — fewer than ten, so there is no comparison to draw.
85 of the studies in Asthma with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT07645248Phase 3GlaxoSmithKlineA Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a) | 2026-12-28 |
| NCT06052267Phase 3Teva Branded Pharmaceutical Products R&D LLCA Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations | 2026-12-31 |
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
| NCT07671001Phase 3GlaxoSmithKlineA Study of Depemokimab in Participants of 6 to 11 Years of Age | 2027-03-01 |
Add all 85 to your calendar (.ics) → With an account.
Among the 1,695 studies in Asthma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is testing the safety, tolerability, pharmacokinetics and pharmacodynamics of GB-0895.
Inclusion Criteria (Part A \& B, Asthma):
Exclusion Criteria (Part A \& B, Asthma):
Inclusion Criteria (Part C, ):
Exclusion Criteria (Part C, COPD):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
randomized 3:1 active:placebo
Biological: GB-0895 (SC) · Drug: Placebo (SC)
randomized 3:1 active:placebo
Biological: GB-0895 (SC) · Drug: Placebo (SC)
randomized 3:1 active:placebo
Biological: GB-0895 (SC) · Drug: Placebo (SC)
Single subcutaneous dose of GB-0895
Multiple subcutaneous doses of GB-0895
Single subcutaneous dose of placebo
Multiple subcutaneous doses of placebo
Number of participants with treatment related adverse events as assessed by CTCAE 5.0
Time frame: Day 1 to Day 500
Measure of maximum plasma concentration of GB-0895
Time frame: Day 1 to Day 500
Total exposure of GB-0895 (AUC)
Time frame: Day 1 to Day 500
Blood eosinophil counts
Time frame: Day 1 to Day 500
Incidence of treatment-emergent anti-drug antibody (ADA) response
Time frame: Day 1 to Day 500
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2023 (actual). Primary completion is estimated for May 2027, 41 months after the start.
Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's planned 41 months is above that.
Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GB-0895
Generate Biomedicines